CoChat
Sign Up
Cited by 18

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

The Role of Psychobiological and Neuroendocrine Mechanisms in Appetite Regulation and Obesity

Paspala, Ioanna, Katsiki, Niki, Kapoukranidou, Dorothea, Mikhailidis, Dimitri P, Tsiligiroglou-Fachantidou, Anna·2012·The Open Cardiovascular Medicine Journal
DOI 10.2174/1874192401206010147PMC PMC3549543
Open this paper in CoChat — free account

Abstract

Obesity is a multifactorial disease. Among its causes are physical inactivity and overeating. In addition, other factors may play an important role in the development of overweight/obesity. For example, certain hormones including leptin, insulin and ghrelin, may influence appetite and consequently body weight. Obesity frequently co-exists with metabolic disorders including dyslipidemia, hypertension and insulin resistance, thus constituting the metabolic syndrome which is characterized by increased cardiovascular risk. Lack of comprehensive knowledge on obesity-related issues makes both prevention and treatment difficult. This review considers the psychobiological and neuroendocrine mechanisms of appetite and food intake. Whether these factors, in terms of obesity prevention and treatment, will prove to be relevant in clinical practice (including reducing the cardiovas-cular risk associated with obesity) remains to be established.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1874192401206010147

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 14 references

Research works printed but not linked: 119

  1. Smit HJ, Kemsley EK, Tapp HS, et al. Does prolonged chewing reduce food intake? Fletcherism revisited Appetite 2011; 57 : 295-8. · DOI
  2. Booth DA. Physiological regulation through learnt control of appe-tites by contingencies among signals from external and internal en-vironments Appetite 2008; 51 : 433-1. · DOI
  3. Soboleva U, Laurina L, Slaidina A. The masticatory system--an overview Stomatologija 2005; 7 : 77-80.
  4. Bourne MC. Food Texture and Viscosity: Concept and Measurement In: Elsevier Science & Technology Book. 2nd ed. USA: Academic Press 2002.
  5. Booth DA. Learnt reduction in the size of a meal. Measurement of the sensory-gastric inhibition of eating from conditioned satiety Appetite 2009; 52 : 745-9. · DOI
  6. Zheng H, Patterson LM, Berthoud HR. Orexin signaling in the ventral tegmental area is required for high-fat. appetite induced by opioid stimulation of the nucleus accumbens J Neurosci 2007; 27 : 11075-82. · DOI · Paper page
  7. Berthoud HR, Morrison C. The brain, appetite, and obesity Annu Rev Psychol 2008; 59 : 55-92. · DOI
  8. Booth DA. The basics of quantitative judgment. How to rate the strength of appetite for food and its sating Appetite 2009; 53 : 438-1. · DOI
  9. Janssen P, Vanden Berghe V, Verschueren S, et al. Review Article: the role of gastric motility in the control of food intake Aliment Pharmacol Ther 2011; 33 : 880-94. · DOI
  10. Rogers PJ. Eating habits and appetite control: a psychobiological perspective Proc Nutr Soc 1999; 58 : 59-67. · DOI
  11. Dhillo WS. Appetite regulation: an overview Thyroid 2007; 17 : 433-5. · DOI
  12. Monro JA, Mishra S. Glycemic impact as a property of foods is accurately measured by an available carbohydrate method that mimics the glycemic response J Nutr 2010; 140 : 1328-34. · DOI
  13. Rolls BJ, Roe LS, Meengs JS. Reductions in portion size and en-ergy density of foods are additive and lead to sustained decreases in energy intake Am J Clin Nutr 2006; 83 : 1-7. · DOI
  14. Renaldi O, Pramono B, Sinorita H, et al. Hypoadiponectinemia: A risk factor for metabolic syndrome Acta Med Indones 2009; 41 : 20-4.
  15. Rolls ET. Brain mechanisms underlying flavour and appetite Philos Trans R Soc Lond B Biol Sci 2006; 361 : 1123-36. · DOI
  16. Campfield LA, Smith FJ. Blood glucose dynamics and control of meal initiation: a pattern detection and recognition theory Physiol Rev 2003; 83 : 25-58. · DOI
  17. Kendall CWC, Esfahani A, Sanders LM, et al. The effect of a pre-load meal containing resistant starch on spontaneous food intake and glucose and insulin responses J Food Technol 2010; 8 : 67-73. · DOI
  18. Joseph RJ, Alonso-Alonso M, Bond DS, et al. The neurocognitive connection between physical activity and eating behaviour Obes Rev 2011; 12 : 800-12. · DOI
  19. Sandoval DA, Ryan KK, Kloet AD, et al. Female rats are relatively more sensitive to reduced lipid versus reduced carbohydrate avail-ability Nutr Diabetes 2012; 2 : e27. · DOI
  20. Halton ThL, Hu FB. The effects of high protein diets on ther-mogenesis, satiety and weight loss: a critical review J Am Coll Nutr 2004; 23 : 373-85. · DOI · Paper page
  21. Henry S. Koopmans. Hepatic control of food intake Appetite 1984; 5 : 127-31. · DOI
  22. Nicolaidis S. What determines food intake? the ischymetric theory Physiology 1987; 2 : 104-7. · DOI
  23. Nicolaidis S, Even P. Physiological determinant of hunger, satia-tion, and satiety Am J Clin Nutr 1985; 42 : 1083-92. · DOI
  24. Booth DA. Lines, dashed lines and “scale” ex-tricks. Objective measurements of appetite versus subjective tests of intake Appetite 2009; 53 : 434-7. · DOI
  25. Lutter M, Nestle EJ. Homeostatic and hedonic signals interact in the regulation of food intake J Nutr 2009; 139 : 629-32. · DOI · Paper page
  26. Griffioen-Roose S, Mars M, Siebelink E, et al. Protein status elicits compensatory changes in food intake and food preferences Am J Clin Nutr 2012; 95 : 32-8. · DOI · Paper page
  27. Veldhorst M, Smeets MA, Soenen S, et al. Protein-induced satiety: Effects and mechanismsof different proteins Physiol Behav 2008; 94 : 300-7. · DOI · Paper page
  28. Hall WL, Millward DJ, Long SJ, et al. Casein and whey exert different effects on plasma amino acid profiles, gastrointestinal hormone secretion and appetite Br J Nutr 2003; 89 : 239-48. · DOI
  29. Havel PJ. Section IV: Lipid modulators of islet function. update on adipocytes hormones regulation of energy balance and carbohydrate/lipid metabolism Diabetes 2004; 53 : S143-51. · DOI
  30. Luhovyy BL, Akhavan T, Anderson GH. Whey proteins in the regulation of food intake and satiety J Am Coll Nutr 2007; 26 : 704S-12S. · DOI
  31. Pupovac J, Anderson GH. Dietary peptides induce satiety via cholecystokinin-a and peripheral opioids receptors in rats J Nutr 2002; 3 : 2775-80. · DOI
  32. Ritter RC. Gastrointestinal mechanisms of satiation for food Physiol Behav 2004; 81 : 249-73. · DOI
  33. Van der Horst K, Oenema A, Ferreira I, et al. A systematic review of environmental correlates of obesity-related dietary behaviours in youth Health Educ Res 2006; 22 : 203-6. · DOI
  34. Leigh GE. Emotional influences on food choice: Sensory, physio-logical and psychological pathways Physiol Behav 2006; 1 : 53-61. · DOI
  35. Ahima RS, Antwi DA. Brain regulation of appetite and satiety J Endocrinol Metab Clin North Am 2008; 37 : 811-23. · DOI
  36. Christensen L. Functional food carbohydrates. RC Press 2006; pp. 435-69. · DOI
  37. EUFIC. Appetite – it’s a brain thing. Neural ensemble coding of satiety states Neuron 2006; 51 : 483-94. · DOI
  38. Valassi E, Scacchi M, Cavagnini F. Neuroendocrine control of food intake Nutr Metab Cardiovasc Dis 2008; 18 : 158-68. · DOI
  39. Williams KW, Scott MM, Elmquist JK. From observation to ex-perimentation: leptin action in the mediobasal hypothalamus Am J Clin Nutr 2009; 89 : 985S-0S. · DOI
  40. Lee CM, Huxley RR, Wildman RP, Woodward M. Indices of ab-dominal obesity are better discriminators of cardiovascular risk fac-tors than BMI: a meta-analysis J Clin Epidemiol 2008; 61 : 646-53. · DOI · Paper page
  41. De Koning L, Merchant AT, Pogue J, Anand SS. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies Eur Heart J 2007; 28 : 850-6. · DOI · Paper page
  42. Asia Pacific Cohort Studies Collaboration. Central obesity and risk of cardiovascular disease in the Asia Pacific Region Asia Pac J Clin Nutr 2006; 15 : 287-92.
  43. Alberti KG, Eckel RH, Grundy SM, et al. International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; In-ternational Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Asso-ciation; World Heart Federation; International Atherosclerosis So-ciety; and International Association for the Study of Obesity Circulation 2009; 120 : 1640-5. · DOI · Paper page
  44. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 2002; 106 : 3143-21. · DOI · Paper page
  45. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition Lancet 2005; 366 (9491 ) : 1059-62. · DOI · Paper page
  46. Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation 2005; 112 : 2735-52. · DOI · Paper page
  47. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation Diabet Med 1998; 15 : 539-. · DOI
  48. Bachar GN, Dicker D, Kornowski R, Atar E. Epicardial adipose tissue as a predictor of coronary artery disease in asymptomatic subjects Am J Cardiol 2012; 110 : 534-8. · DOI
  49. Sacks HS, Fain JN. Human epicardial fat: what is new and what is missing? Clin Exp Pharmacol Physiol 2011; 38 : 879-. · DOI
  50. Karayannis G, Giamouzis G, Tziolas N, et al. Association between epicardial fat thickness and weight homeostasis hormones in patients with noncachectic heart failure Angiology 2012 May 30; [Epub ahead of print]
  51. Sahu A. Leptin signalling in the hypothalamus: emphasis on energy homeostasis and leptin resistance Front Neuroendocrinol 2003; 24 : 225-53. · DOI
  52. Koch A, Weiskirchen R, Zimmermann HW, et al. Relevance of serum leptin and leptin-receptor concentrations in critically Ill patients Mediators Inflamm 2010 2010; pii:473540.
  53. Hroussalas G, Kassi E, Dalamaga M, et al. Leptin, soluble leptin receptor, adiponectin and resistin in relation to OGTT in over-weight/obese postmenopausal women Maturitas 2008; 59 : 339-49. · DOI
  54. Kelesidis T, Kelesidis I, Chou S, et al. Narrative review: the role of leptin in human physiology: emerging clinical applications Ann Intern Med 2010; 152 : 93-100. · DOI
  55. Flakoll PJ, Jensen MD, Cherrington AD. Diabetes mellitus: a fun-damental and clinical text. 3rd ed. Philadelphia: Lippincott Wil-liams & Wilkins 2004.
  56. Szanto I, Kahn CR. Selective interaction between leptin and insulin signalling pathways in a hepatic cell line Proc Natl Acad Sci 2000; 97 : 2355-60. · DOI
  57. Margetic S, Gazzola C, Pegg1 GG, Hill RA. Leptin: a review of its peripheral actions and interactions Int J Obes Relat Metab Disord 2002; 6 : 1407-33. · DOI
  58. Enriori PJ, Evans AE, Sinnayah P, et al. Leptin resistance and obesity Obesity 2006; 14 : 254-8. · DOI · Paper page
  59. Belgardt BF, Brüning JC. CNS leptin and insulin action in the control of energy homeostasis Ann NY Acad Sci 2010; 1212 : 97-113. · DOI
  60. Wilcox G. Insulin and insulin resistance Clin Biochem Rev 2005; 26 : 19-39.
  61. Malendowicz W, Rucinski M, Macchi C, et al. Leptin and leptin receptors in the prostate and seminal vesicles of the adult rat Int J Mol Med 2006; 18 : 615-8.
  62. Ukkola O, Poykko S. Ghrelin growth and obesity Ann Med 2002; 34 : 102-8. · DOI
  63. Strat AL, Kokta ThA, Dodson MV, et al. Early signalling interac-tions between the insulin and leptin pathways in bovine myogenic cells Biochim Biophys Acta 2005; 1744 : 164-75. · DOI
  64. Selenscig D, Rossi A, Chicco A, et al. Increased leptin storage with altered leptin secretion from adipocytes of rats with sucrose-induced dyslipidemia and insulin resistance: effect of dietary fish oil Metabolism 2010; 59 : 787-95. · DOI
  65. Jequier E. Leptin signalling, adiposity, and energy balance Ann NY Acad Sci 2002; 967 : 379-88. · DOI
  66. Singh A, Wirtz M, Parker N, et al. Leptin-mediated changes in hepatic mitochondrial metabolism, structure, and protein levels Proc Natl Acad Sci 2009; 106 : 13100-5. · DOI
  67. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents Nature 2000; 407 : 908-13. · DOI · Paper page
  68. Truett GE, Parks EJ. Ghrelin: It’s role in energy balance J Nutr 2005; 135 : 1313. · DOI
  69. Hameed S, Dhillo WS, Bloom SR. Gut hormones and appetite control Oral Dis 2009; 15 : 18-26. · DOI
  70. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth –hormone- releasing acylated peptide from stomach Nature 1999; 402 : 656-0. · DOI · Paper page
  71. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery N Engl J Med 2002; 346 : 1623-30. · DOI
  72. Johnstone LE, Srisawat R, Kumarnsit E, et al. Hypothalamic ex-pression of NPY mRNA, vasopressin mRNA and CRF mRNA in response to food restriction and central administration of the orexi-genic peptide GHRP-6 Stress 2005; 8 : 59-67. · DOI
  73. Kishimoto I, Tokudome T, Hosoda H, Miyazato M, Kangawa K. Ghrelin and cardiovascular diseases J Cardiol 2012; 59 : 8-13. · DOI
  74. Sudar E, Dobutovic B, Soskic S, et al. Regulation of inducible nitric oxide synthase activity/expression in rat hearts from ghrelin-treated rats J Physiol Biochem 2011; 67 : 195-204. · DOI
  75. Beaumont NJ, Skinner VO, Tan TM, et al. Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase J Biol Chem 2003; 278 : 8877-0. · DOI
  76. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein Curr Opin Cardiol 2008; 23 : 370-8. · DOI
  77. Makimura H, Feldpausch MN, Stanley TL, Sun N, Grinspoon SK. Reduced growth hormone secretion in obesity is associated with smaller LDL and HDL particle size Clin Endocrinol (Oxf) 2012; 76 : 220-7. · DOI
  78. Mikhailidis DP, Elisaf M, Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the patho-physiology, atherogenicity and clinical significance of LDL sub-classes Curr Vasc Pharmacol 2011; 9 : 533-71. · DOI
  79. Florentin M, Tselepis AD, Elisaf MS, Rizos CV, Mikhailidis DP, Liberopoulos EN. Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipi-daemia Curr Vasc Pharmacol 2010; 8 : 820-30. · DOI
  80. Gazi IF, Tsimihodimos V, Tselepis AD, Elisaf M, Mikhailidis DP. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles Expert Opin Biol Ther 2007; 7 : 53-72. · DOI
  81. Agouridis AP, Kostapanos MS, Tsimihodimos V, et al. Effect of rosuvastatin monotherapy or in combination with fenofibrate or ?-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome Int J Clin Pract 2012; 66 : 843-53. · DOI
  82. Rizzo M, Mikhailidis DP. Lipoprotein alterations and reduced growth hormone secretion: relationships with obesity and cardio-vascular risk Clin Endocrinol (Oxf) 2012; 76 : 177-8. · DOI
  83. Germain N, Galusca B, Le Roux CW, et al. Constitutional thinness and lean anorexia nervosa display opposite concentrations of pep-tide YY, glucagon –like peptide 1, ghrelin and leptin Am J Clin Nutr 2007; 85 : 967-71. · DOI
  84. Budak E, Sánchez MF, Bellver J, et al. Interactions of the hor-mones leptin, ghrelin, adiponectin, resistin, and PYY3-36 with the reproductive system Fertil Steril 2006; 85 : 1563-81. · DOI
  85. Stylianou Ch, Galli-Tsinopoulou A, Farmakiotis D, et al. Ghrelin and leptin levels in obese adolescents. Relationship with body fat and insulin resistance Hormones 2007; 6 : 295-303. · DOI
  86. Diez JJ, Iglesias P. The role of the novel adipocytes-derived hor-mone adiponectin in human disease Eur J Endocrinol 2003; 148 : 293-300. · DOI
  87. Kraemer FB, Shen WJ. Hormone-sensitive lipase knockouts Nutr Metabol 2006; 3 : 12. · DOI
  88. Athyros VG, Ganotakis ES, Tziomalos K, et al. Comparison of four definitions of the metabolic syndrome in a Greek (Mediterra-nean) population Curr Med Res Opin 2010; 26 : 713-9. · DOI
  89. Chimonas T, Athyros VG, Ganotakis E, et al. Assessing the treat-ment effect in metabolic syndrome without perceptible diabetes (at-tempt) collaborative group. cardiovascular risk factors and esti-mated 10-year risk of fatal cardiovascular events using various equations in greeks with metabolic syndrome Angiology 2010; 61 : 49-57. · DOI
  90. Hu B, Zhou Y, Liu Y, et al. Impact of metabolic syndrome on clinical outcomes after drug-eluting stent implantation in patients with coronary artery disease Angiology 2011; 62 (6 ) : 440-6. · DOI
  91. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis J Am Coll Cardiol 2010; 56 : 1113-32. · DOI · Paper page
  92. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis Am J Med 2006; 119 : 812-9. · DOI
  93. Athyros VG, Hatzitolios AI, Karagiannis A, et al. Imperative Col-laborative Group. IMproving the implementation of current guide-lines for the management of major coronary heart disease risk fac-tors by multifactorial intervention. The imperative renal analysis Arch Med Sci 2011; 7 : 984-2. · DOI
  94. Athyros VG, Ganotakis E, Kolovou GD, et al. Assessing the treat-ment effect in metabolic syndrome without perceptible diabetes (Attempt) collaborative. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (attempt): a prospective-randomized study in middle aged men and women Curr Vasc Pharmacol 2011; 9 : 647-57. · DOI
  95. Athyros VG, Karagiannis A, Hatzitolios AI, et al. SAGE-METS collaborative group. Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study Curr Med Res Opin 2009; 25 : 971-80. · DOI
  96. Katsiki N, Mikhailidis DP, Gotzamani-Psarrakou A, et al. Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus Expert Opin Ther Targets 2011; 15 : 401-20. · DOI
  97. Katsiki N, Mikhailidis DP, Gotzamani-Psarrakou A, et al. Effects of improving glycemic control with insulin on leptin, adiponectin, ghrelin and neuropeptide y levels in patients with type 2 diabetes mellitus: a pilot study Open Cardiovasc Med J 2011; 5 : 136-47. · DOI
  98. Florentin M, Liberopoulos EN, Tellis CC, Derdemezis CS, Elisaf M, Tselepis A. Effects of rimonabant, as monotherapy and in com-bination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study Angiology 2010; 61 : 365-71. · DOI
  99. Filippatos TD, Mikhailidis DP. Lipid-lowering drugs acting at the level of the gastrointestinal tract Curr Pharm Des 2009; 15 : 490-516. · DOI
  100. Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mik-hailidis DP, Elisaf MS. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the Fenorli study Curr Med Res Opin 2005; 21 : 1997-2006. · DOI
  101. Florentin M, Liberopoulos EN, Filippatos TD, et al. Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study Expert Opin Pharmacother 2008; 9 : 2741-50. · DOI
  102. Kakafika AI, Mikhailidis DP, Karagiannis A, Athyros VG. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome J Clin Pharmacol 2007; 47 : 642-52. · DOI
  103. Le Foll B, Gorelick DA, Goldberg SR. The future of endocannabi-nod-oriented clinical research after CB1 antagonists Psychophar-macology (Berl) 2009; 205 : 71-4.
  104. Czernichow S, Batty D. Withdrawal of sibutramine for weight loss: where does this leave clinicians? Obes Facts 2010; 3 : 155-6. · DOI
  105. Florentin M, Liberopoulos EN, Elisaf MS. Sibutramine-associated adverse effects: a practical guide for its safe use Obes Rev 2008; 9 : 378-87. · DOI
  106. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review Drug Saf 2008; 31 : 53-65. · DOI
  107. Katsiki N, Hatzitolios AI, Mikhailidis DP. Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'? Ann Med 2011; 43 : 249-58. · DOI
  108. Bays HE, Gadde KM. Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity Drugs Today (Barc) 2011; 47 : 903-14. · DOI
  109. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP) Obesity (Silver Spring) 2012; 20 : 330-42. · DOI · Paper page
  110. Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J. Drug-induced fibrotic valvular heart disease Lancet 2009; 374 : 577-85. · DOI
  111. Heal DJ, Gosden J, Smith SL. What is the prognosis for new cen-trally-acting antiobesity drugs? Neuropharmacology 2012; 63 : 132-46. · DOI
  112. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment Open Cardiovasc Med J 2011; 5 : 24-34. · DOI
  113. Athyros VG, Tziomalos K, Karagiannis A, Anagnostis P, Mik-hailidis DP. Should adipokines be considered in the choice of the treatment of obesity-related health problems? Curr Drug Targets 2010; 11 : 122-35. · DOI
  114. Filippatos TD, Randeva HS, Derdemezis CS, Elisaf MS, Mik-hailidis DP. Visfatin/PBEF and atherosclerosis-related diseases Curr Vasc Pharmacol 2010; 8 : 12-28. · DOI
  115. Filippatos TD, Derdemezis CS, Gazi IF, et al. Increased plasma visfatin levels in subjects with the metabolic syndrome Eur J Clin Invest 2008; 38 : 71-2. · DOI
  116. Malo E, Ukkola O, Jokela M, et al. Resistin is an indicator of the metabolic syndrome according to five different definitions in the Finnish Health 2000 survey Metab Syndr Relat Disord 2011; 9 : 203-10. · DOI
  117. Christou GA, Tselepis AD, Kiortsis DN. The metabolic role of retinol binding protein 4: an update Horm Metab Res 2012; 44 : 6-14. · DOI
  118. Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review Diabetes Metab Res Rev 2011; 27 : 515-27. · DOI
  119. Shaker O, El-Shehaby A, Zakaria A, et al. Plasma visfatin and retinol binding protein-4 levels in patients with type 2 diabetes mellitus and their relationship to adiposity and fatty liver Clin Biochem 2011; 44 : 1457-6. · DOI

Cited by

Sorted by citations

See all 18

Metadata

Authors
Paspala, I., Katsiki, N., Kapoukranidou, D., Mikhailidis, D. P., & Tsiligiroglou-Fachantidou, A.
Venue
The Open Cardiovascular Medicine Journal
Publisher
Bentham Science Publishers Ltd.
Published
2012-12-28
Volume
6
Issue
1
Pages
147-155
ISSN
1874-1924
DOI
10.2174/1874192401206010147
PMC
PMC3549543
Cited by
18
References
14
Language
en
Licence
creativecommons.org/licenses/by-nc/3.0/ (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review